BeiGene lung cancer drug tislelizumab meets primary goal in trial

Non-small cell carcinoma of the lung is considered as the most common lung cancer in China. Credit: Ed Uthman.



  • BeiGene lung cancer drug tislelizumab meets primary goal in Phase III trial